Piper Jaffray Companies reissued their hold rating on shares of Celgene (NASDAQ:CELG) in a research note released on Thursday morning. The brokerage currently has a $104.00 price objective on the biopharmaceutical company’s stock.

Other analysts have also recently issued research reports about the stock. UBS Group cut shares of Celgene from a strong-buy rating to a market perform rating and set a $160.00 price target on the stock. in a research report on Thursday, October 26th. BMO Capital Markets cut their price target on shares of Celgene from $163.00 to $148.00 and set an outperform rating on the stock in a research report on Friday, October 27th. Robert W. Baird cut shares of Celgene from an outperform rating to a neutral rating and cut their price target for the company from $162.00 to $136.00 in a research report on Friday, October 20th. BTIG Research reaffirmed a hold rating on shares of Celgene in a research report on Sunday, October 22nd. Finally, Vetr raised shares of Celgene from a buy rating to a strong-buy rating and set a $144.39 price target on the stock in a research report on Monday, October 23rd. Two analysts have rated the stock with a sell rating, thirteen have issued a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the company. Celgene currently has a consensus rating of Buy and an average target price of $129.98.

Shares of Celgene (NASDAQ:CELG) traded up $0.93 on Thursday, reaching $102.65. 8,110,000 shares of the company’s stock were exchanged, compared to its average volume of 6,700,000. The company has a quick ratio of 3.52, a current ratio of 3.65 and a debt-to-equity ratio of 1.31. The company has a market capitalization of $80,820.00, a PE ratio of 24.21, a P/E/G ratio of 0.66 and a beta of 1.77. Celgene has a twelve month low of $94.55 and a twelve month high of $147.17.

Celgene (NASDAQ:CELG) last issued its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 EPS for the quarter, beating the Zacks’ consensus estimate of $1.87 by $0.04. The business had revenue of $3.29 billion for the quarter, compared to analysts’ expectations of $3.42 billion. Celgene had a net margin of 27.36% and a return on equity of 63.80%. The business’s quarterly revenue was up 10.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.58 earnings per share. research analysts forecast that Celgene will post 6.71 EPS for the current fiscal year.

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Capital Counsel LLC NY raised its holdings in shares of Celgene by 0.4% in the 2nd quarter. Capital Counsel LLC NY now owns 1,649 shares of the biopharmaceutical company’s stock worth $214,000 after acquiring an additional 6 shares during the last quarter. Fort Pitt Capital Group LLC raised its holdings in shares of Celgene by 0.6% in the 2nd quarter. Fort Pitt Capital Group LLC now owns 1,925 shares of the biopharmaceutical company’s stock worth $250,000 after acquiring an additional 11 shares during the last quarter. Savant Capital LLC raised its holdings in shares of Celgene by 0.9% in the 2nd quarter. Savant Capital LLC now owns 2,350 shares of the biopharmaceutical company’s stock worth $305,000 after acquiring an additional 20 shares during the last quarter. TCI Wealth Advisors Inc. raised its holdings in shares of Celgene by 0.9% in the 2nd quarter. TCI Wealth Advisors Inc. now owns 3,043 shares of the biopharmaceutical company’s stock worth $395,000 after acquiring an additional 26 shares during the last quarter. Finally, Granite Investment Advisors LLC raised its holdings in shares of Celgene by 1.1% in the 2nd quarter. Granite Investment Advisors LLC now owns 2,579 shares of the biopharmaceutical company’s stock worth $352,000 after acquiring an additional 29 shares during the last quarter. Institutional investors own 79.85% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This news story was first reported by Daily Political and is the sole property of of Daily Political. If you are accessing this news story on another domain, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be accessed at https://www.dailypolitical.com/2018/01/21/piper-jaffray-companies-reaffirms-hold-rating-for-celgene-celg.html.

Celgene Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Analyst Recommendations for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.